Covered recipient · General Payments record
TERRY D KLEIN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$777.29
67 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $733.52 | 65 |
| Education | $32.27 | 1 |
| Gift | $11.50 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $155.09 | 12 |
| Novo Nordisk Inc | $150.68 | 12 |
| Allergan, Inc. | $114.90 | 14 |
| Eisai Inc. | $51.30 | 4 |
| Amarin Pharma Inc. | $50.66 | 4 |
| SANOFI-AVENTIS U.S. LLC | $47.57 | 3 |
| Teva Pharmaceuticals USA, Inc. | $45.78 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $29.34 | 2 |
| IRONWOOD PHARMACEUTICALS, INC | $26.39 | 2 |
| Abbott Laboratories | $16.52 | 1 |
| Vanda Pharmaceuticals Inc. | $14.38 | 1 |
| Merck Sharp & Dohme Corporation | $14.18 | 3 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.62 | 1 |
| Otsuka America Pharmaceutical, Inc. | $12.20 | 1 |
| GlaxoSmithKline, LLC. | $12.10 | 1 |
| SANOFI PASTEUR INC. | $11.50 | 1 |
| AbbVie Inc. | $11.08 | 1 |
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
TERRY D KLEIN
NPI 1831151406 · CMS profile ID 219070
Allopathic & Osteopathic Physicians / Family Medicine
WICHITA, KS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1831151406?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- TERRY D KLEIN, NPI 1831151406, CMS profile ID 219070. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831151406?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). TERRY D KLEIN, NPI 1831151406, CMS profile ID 219070. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831151406?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- TERRY D KLEIN, NPI 1831151406, CMS profile ID 219070, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1831151406?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
67 matching records · $777.29 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–67 of 67.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $14.38 | 05/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735135153 | CMS |
| Amarin Pharma Inc. | $11.42 | 05/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740058045 | CMS |
| SANOFI-AVENTIS U.S. LLC | $15.20 | 04/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744090201 | CMS |
| SANOFI-AVENTIS U.S. LLC | $18.75 | 04/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744090197 | CMS |
| Amgen Inc. | $18.63 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741332015 | CMS |
| Novo Nordisk Inc | $32.27 | 03/09/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744580049 | CMS |
| Novo Nordisk Inc | $11.41 | 03/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744727899 | CMS |
| Teva Pharmaceuticals USA, Inc. | $11.29 | 03/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 749479897 | CMS |
| Amgen Inc. | $11.52 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741332013 | CMS |
| Allergan, Inc. | $13.22 | 02/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723693727 | CMS |
| Otsuka America Pharmaceutical, Inc. | $12.20 | 02/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748740501 | CMS |
| Novo Nordisk Inc | $12.62 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744626293 | CMS |
| Allergan, Inc. | $10.24 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723693725 | CMS |
| Allergan, Inc. | $1.26 | 01/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 723693723 | CMS |
| Amgen Inc. | $12.88 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741331997 | CMS |
| Amgen Inc. | $12.98 | 01/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741332011 | CMS |
| Merck Sharp & Dohme Corporation | $4.08 | 01/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747682103 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,685,196.04 | 262 |
| PY2024 | Recipient | $3,360.61 | 19 |
| PY2024 | Principal investigator | $1,074,057.00 | 79 |
| PY2023 | Principal investigator | $1,033,581.13 | 84 |
| PY2022 | Principal investigator | $908,725.19 | 32 |
| PY2021 | Principal investigator | $493,490.89 | 34 |
| PY2020 | Principal investigator | $198,016.78 | 27 |
| PY2019 | Principal investigator | $549,472.20 | 59 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
262 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202533113 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202533115 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $55,309.34 | 12/31/2025 | Non-covered Recipient Entity AMR Clinical - Wichita | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent | No dispute reported | 06/30/2026 | 1232937284 |
| Principal investigator 1 | PFIZER INC. | $454.50 | 12/29/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228724490 |
| Principal investigator 1 | PFIZER INC. | $351.00 | 12/29/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728313 |
| Principal investigator 1 | PFIZER INC. | $454.50 | 12/29/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728541 |
| Principal investigator 1 | PFIZER INC. | $351.00 | 12/29/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228729021 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,640.25 | 12/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715520 |
| Principal investigator 1 | PFIZER INC. | $138.30 | 12/24/2025 | Non-covered Recipient Entity Alliance for Multi Res | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228728091 |
| Principal investigator 1 | PFIZER INC. | $123.10 | 12/24/2025 | Non-covered Recipient Entity Alliance for Multi Res | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228729594 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228719741 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228720627 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228724946 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228724948 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725128 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725288 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725380 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228725382 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228730788 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735349 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735353 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735585 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735589 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735694 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735949 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735953 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228735957 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738659 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738807 |
| Principal investigator 1 | PFIZER INC. | $426.60 | 12/23/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228738811 |
| Principal investigator 1 | PFIZER INC. | $303.00 | 12/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228726286 |
| Principal investigator 1 | PFIZER INC. | $351.00 | 12/18/2025 | Non-covered Recipient Entity AMR Clinical | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228728093 |
| Principal investigator 1 | Vanda Pharmaceuticals Inc. | $11,500.00 | 12/17/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension | No dispute reported | 06/30/2026 | 1232947218 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $399.00 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798915 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,165.00 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798917 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,536.20 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798919 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,236.28 | 12/15/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798921 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $159.00 | 12/12/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517682 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,250.00 | 12/12/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107706 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $56.22 | 12/12/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107712 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $17,325.20 | 12/11/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715512 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $21,970.40 | 12/10/2025 | Non-covered Recipient Entity AMR Clinical - Wichita | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent | No dispute reported | 06/30/2026 | 1232937282 |
| Principal investigator 1 | ABBVIE INC. | $3,064.30 | 12/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202527446 |
| Principal investigator 1 | ABBVIE INC. | $2,749.92 | 12/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202527692 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,908.45 | 12/03/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721730 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721732 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721734 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721736 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721738 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721740 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $3,687.60 | 11/21/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107439 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 11/20/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202524838 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $2,341.75 | 11/13/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715510 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,665.43 | 11/12/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214736 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $129.00 | 11/06/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220807403 |
| Principal investigator 1 | ABBVIE INC. | $3,705.38 | 11/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522065 |
| Principal investigator 1 | ABBVIE INC. | $539.20 | 11/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202520477 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721724 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721726 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721728 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $106.00 | 10/29/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517686 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,796.36 | 10/29/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798913 |
| Principal investigator 1 | PFIZER INC. | $1,061.20 | 10/28/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228741631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $399.60 | 10/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721742 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $912.50 | 10/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.50 | 10/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721746 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $27.60 | 10/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721748 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $27,042.40 | 10/23/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research Llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226107501 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $4,977.50 | 10/14/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715490 |
| Principal investigator 1 | ABBVIE INC. | $4,583.20 | 10/09/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202515533 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 10/08/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228730537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721706 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721708 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721710 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721712 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721716 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $821.00 | 10/01/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798911 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,885.88 | 09/26/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214718 |
| Principal investigator 1 | PFIZER INC. | $13,589.80 | 09/24/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228752456 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,278.60 | 09/18/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798909 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/18/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220807401 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $893.17 | 09/17/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517543 |
| Principal investigator 1 | ABBVIE INC. | $5,500.00 | 09/16/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202511032 |
| Principal investigator 1 | ABBVIE INC. | $3,064.30 | 09/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202509316 |
| Principal investigator 1 | PFIZER INC. | $6,097.00 | 09/03/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228758289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721676 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721680 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721682 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721684 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721702 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 08/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008724 |
| Principal investigator 1 | ModernaTX, Inc. | $98.80 | 08/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008760 |
| Principal investigator 1 | PFIZER INC. | $27,628.00 | 08/28/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228768347 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,816.90 | 08/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517547 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,654.71 | 08/08/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214704 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.80 | 08/08/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214706 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,422.80 | 08/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798907 |
| Principal investigator 1 | ABBVIE INC. | $1,358.78 | 08/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202501590 |
| Principal investigator 1 | Bavarian Nordic A/S | $9,606.72 | 08/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214696 |
| Principal investigator 1 | Bavarian Nordic A/S | $152.00 | 08/01/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214722 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721664 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721668 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721670 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721672 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721696 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721700 |
| Principal investigator 1 | ABBVIE INC. | $960.00 | 07/31/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202500790 |
| Principal investigator 1 | ABBVIE INC. | $1,500.00 | 07/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202500542 |
| Principal investigator 1 | ModernaTX, Inc. | $854.02 | 07/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008720 |
| Principal investigator 1 | PFIZER INC. | $1,451.80 | 07/25/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228723532 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,967.82 | 07/16/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517550 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 07/16/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228765403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,476.00 | 07/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798903 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,072.00 | 07/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798905 |
| Principal investigator 1 | ABBVIE INC. | $3,064.30 | 07/02/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202496563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721686 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721688 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721690 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721692 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721694 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721698 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 06/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008734 |
| Principal investigator 1 | ModernaTX, Inc. | $3,757.00 | 06/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008746 |
| Principal investigator 1 | ModernaTX, Inc. | $230.00 | 06/30/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008782 |
| Principal investigator 1 | ModernaTX, Inc. | $427.01 | 06/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008774 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,711.72 | 06/26/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $81.62 | 06/24/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $474.50 | 06/24/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721658 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $994.95 | 06/24/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721660 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $17.40 | 06/24/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721662 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,105.00 | 06/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798891 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $900.00 | 06/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798893 |
| Principal investigator 1 | Currax Pharmaceuticals LLC | $1,444.25 | 06/24/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | NB (Contrave) Cardiovascular Outcomes Trial | No dispute reported | 06/30/2026 | 1242715478 |
| Principal investigator 1 | ModernaTX, Inc. | $650.00 | 06/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008714 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,267.00 | 06/20/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113165 |
| Principal investigator 1 | ModernaTX, Inc. | $10,675.25 | 06/18/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008756 |
| Principal investigator 1 | PFIZER INC. | $2,506.00 | 06/14/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228775540 |
| Principal investigator 1 | ABBVIE INC. | $841.08 | 06/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202489251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721634 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721636 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721638 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721640 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721644 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721646 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721648 |
| Principal investigator 1 | ModernaTX, Inc. | $26,474.62 | 05/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008728 |
| Principal investigator 1 | ModernaTX, Inc. | $8,872.24 | 05/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008744 |
| Principal investigator 1 | ModernaTX, Inc. | $7,286.50 | 05/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008776 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 05/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721650 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $912.50 | 05/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721652 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $26.10 | 05/27/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721654 |
| Principal investigator 1 | ModernaTX, Inc. | $149.50 | 05/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008764 |
| Principal investigator 1 | ModernaTX, Inc. | $4,125.70 | 05/23/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008770 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 05/22/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008786 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $893.17 | 05/21/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517797 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $32,942.00 | 05/16/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113738 |
| Principal investigator 1 | ABBVIE INC. | $869.00 | 05/15/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202485139 |
| Principal investigator 1 | PFIZER INC. | $8,433.00 | 05/14/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228766504 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,070.24 | 05/09/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214680 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,762.50 | 05/09/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798899 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,395.80 | 05/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214674 |
| Principal investigator 1 | ABBVIE INC. | $394.96 | 05/06/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202481299 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $1,960.00 | 05/06/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113510 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $371.00 | 05/02/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517770 |
| Principal investigator 1 | Bavarian Nordic A/S | $361.00 | 05/02/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214678 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721620 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721622 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721624 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721626 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721628 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721630 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721632 |
| Principal investigator 1 | PFIZER INC. | $750.00 | 05/01/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228771964 |
| Principal investigator 1 | ModernaTX, Inc. | $7,286.50 | 04/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008736 |
| Principal investigator 1 | ModernaTX, Inc. | $2,989.07 | 04/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008740 |
| Principal investigator 1 | ModernaTX, Inc. | $10,848.24 | 04/28/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008778 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $189,059.40 | 04/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113831 |
| Principal investigator 1 | PFIZER INC. | $2,506.00 | 04/25/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228779444 |
| Principal investigator 1 | PFIZER INC. | $23,581.80 | 04/24/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228797421 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,645.28 | 04/18/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214644 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $2,563.00 | 04/17/2025 | Non-covered Recipient Entity AMR WICHITA EAST KS HEARTLAND RESEARCH ASSOCIATES | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy? | No dispute reported | 06/30/2026 | 1214124174 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 04/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008754 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,728.90 | 04/11/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798897 |
| Principal investigator 1 | PFIZER INC. | $1,864.40 | 04/09/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228779492 |
| Principal investigator 1 | ABBVIE INC. | $480.00 | 04/04/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202474370 |
| Principal investigator 1 | ABBVIE INC. | $1,594.08 | 04/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202470625 |
| Principal investigator 1 | ABBVIE INC. | $1,818.45 | 04/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202470628 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,389.44 | 04/01/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721604 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721606 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721608 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721610 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721612 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721614 |
| Principal investigator 1 | PFIZER INC. | $17,512.60 | 03/28/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228788169 |
| Principal investigator 1 | SANOFI PASTEUR INC. | $18,567.00 | 03/28/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research,llc | A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older | No dispute reported | 06/30/2026 | 1226113424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721616 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 03/25/2025 | Non-covered Recipient Entity Amr Wichita East | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220721618 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $44,756.60 | 03/25/2025 | Non-covered Recipient Entity Alliance For Multispecialty Research LLC | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798895 |
| Principal investigator 1 | ModernaTX, Inc. | $2,740.90 | 03/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008722 |
| Principal investigator 1 | ModernaTX, Inc. | $8,967.21 | 03/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008752 |
| Principal investigator 1 | ModernaTX, Inc. | $9,702.16 | 03/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008768 |
| Principal investigator 1 | ModernaTX, Inc. | $7,286.50 | 03/24/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008784 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,166.00 | 03/21/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517706 |
| Principal investigator 1 | Bavarian Nordic A/S | $11,203.60 | 03/21/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214606 |
| Principal investigator 1 | PFIZER INC. | $10,838.80 | 03/18/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228797762 |
| Principal investigator 1 | ModernaTX, Inc. | $2,475.42 | 03/13/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008718 |
| Principal investigator 1 | ModernaTX, Inc. | $3,978.00 | 03/13/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008732 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,652.80 | 03/12/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517722 |
| Principal investigator 1 | PFIZER INC. | $29,653.40 | 03/12/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228793885 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $76,023.45 | 03/11/2025 | Non-covered Recipient Entity AMR WICHITA EAST KS HEARTLAND RESEARCH ASSOCIATES | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214123566 |
| Principal investigator 1 | ABBVIE INC. | $16,734.20 | 03/07/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202459522 |
| Principal investigator 1 | ABBVIE INC. | $2,892.80 | 03/06/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202456632 |
| Principal investigator 1 | PFIZER INC. | $12,517.40 | 03/04/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228797331 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,487.21 | 03/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214594 |
| Principal investigator 1 | ModernaTX, Inc. | $21,350.50 | 02/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008742 |
| Principal investigator 1 | ModernaTX, Inc. | $11,203.92 | 02/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008748 |
| Principal investigator 1 | ModernaTX, Inc. | $14,573.00 | 02/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008750 |
| Principal investigator 1 | ModernaTX, Inc. | $1,035.98 | 02/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008772 |
| Principal investigator 1 | ModernaTX, Inc. | $10,963.60 | 02/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008780 |
| Principal investigator 1 | PFIZER INC. | $17,465.70 | 02/26/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228762244 |
| Principal investigator 1 | Amgen Inc. | $40,298.04 | 02/25/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246639029 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $12,356.23 | 02/21/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517726 |
| Principal investigator 1 | Bavarian Nordic A/S | $95.00 | 02/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214616 |
| Principal investigator 1 | ABBVIE INC. | $100.00 | 02/06/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202446873 |
| Principal investigator 1 | ABBVIE INC. | $3,175.88 | 02/05/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202443991 |
| Principal investigator 1 | PFIZER INC. | $1,800.00 | 02/05/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research LLC | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228770274 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,290.62 | 02/03/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215517742 |
| Principal investigator 1 | ModernaTX, Inc. | $11,164.40 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008716 |
| Principal investigator 1 | ModernaTX, Inc. | $1,661.26 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008726 |
| Principal investigator 1 | ModernaTX, Inc. | $5,978.14 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008738 |
| Principal investigator 1 | ModernaTX, Inc. | $5,481.80 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008758 |
| Principal investigator 1 | ModernaTX, Inc. | $29,007.44 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008762 |
| Principal investigator 1 | ModernaTX, Inc. | $24,774.10 | 01/27/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008766 |
| Principal investigator 1 | PFIZER INC. | $2,539.20 | 01/25/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228800329 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $4,342.80 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518058 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,108.80 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518062 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $9,702.00 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518065 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,234.00 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518068 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,375.12 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518072 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,178.12 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518105 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $10,881.33 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518109 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,231.44 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518112 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,234.00 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518116 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,108.80 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518120 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,234.00 | 01/22/2025 | Non-covered Recipient Entity Alliance for Multispecialty Research, LLC, Knoxville | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215518131 |
| Principal investigator 1 | ModernaTX, Inc. | $1,250.00 | 01/22/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH LLC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253008730 |
| Principal investigator 1 | PFIZER INC. | $20,270.60 | 01/15/2025 | Non-covered Recipient Entity Alliance for Multispeciality Research LLC | A PHASE 1 RANDOMIZED AND PHASE 2 STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND IMMUNOPERSISTENCE OF A CLOSTRIDIOIDES DIFFICILE VACCINE ADMINISTERED IN A 2DOSE REGIMEN WITH NOVEL ADJUVANTS IN HEALTHY ADULTS | No dispute reported | 06/30/2026 | 1228801104 |
| Principal investigator 1 | ABBVIE INC. | $5,204.15 | 01/14/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202438325 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $24,100.00 | 01/03/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY RESEARCH | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185541198 |
| Principal investigator 1 | ABBVIE INC. | $2,892.80 | 01/02/2025 | Non-covered Recipient Entity ALLIANCE FOR MULTISPECIALTY | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202433530 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $263,667.22 | 01/01/2025 | Non-covered Recipient Entity AMR WICHITA EAST KS HEARTLAND RESEARCH ASSOCIATES | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214123854 |